Notice: amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `pre_get_posts` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the theme with slug `publisher` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/runcloud/webapps/techilive/wp-includes/functions.php on line 5313
COVID Vax Platform Expands; A Devil of a Cancer Link; Talking About the C(ure)-Word -

COVID Vax Platform Expands; A Devil of a Cancer Link; Talking About the C(ure)-Word


The same molecular platform that led to effective vaccines against the novel coronavirus — messenger RNA — has begun expanding into other therapeutic areas, including cancer. (CNN)

Men with a family history of prostate cancer should begin screening for the disease 2 to 11 years earlier than currently recommended, according to an analysis of a large Swedish database. (PLOS Medicine)

A penile traction device increased penile length and improved erectile function in men who had undergone surgery for prostate cancer. (Journal of Urology)


Smoking contributed to almost eight million deaths worldwide in 2019, and 90% of smokers developed nicotine addiction by age 25. (The Lancet, The Lancet Public Health)

The return of the Tasmanian devil to the Australian mainland may have hopeful implications for cancer. (Fox News)

Delaying surgery for early-stage lung cancer more than 12 weeks after diagnosis increased the likelihood of recurrence and death. (Washington University in St. Louis, JAMA Network Open)


EQRx and CStone Pharmaceuticals announced that the anti-PD-L1 antibody sugemalimab significantly improved progression-free survival in non-small cell lung cancer following chemoradiation.

BridgeBio Pharma’s affiliate, QED Therapeutics, as well as Helsinn Group announced that the FDA granted accelerated approval of the fibroblast growth factor receptor inhibitor infigratinib (Truseltiq) for previously treated advanced/metastatic cholangiosarcoma. Read MedPage Today‘s coverage of the pivotal trial that supported the approval.

Body mass index, a widely used method to calculate and define obesity, may not be the best way to evaluate the association between obesity and lung cancer. (Journal of Thoracic Oncology)


Big Pharma asked cancer experts what they think about using the C-word — cure — when talking about cancer therapies. (FiercePharma)

Frequent emergency department visits before cancer may foretell frequent ED visits after cancer diagnosis. (JCO Oncology Practice)

The virtual meeting of the American Society of Clinical Oncology begins Friday and continues through Tuesday. MedPage Today will have complete coverage.

  • Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow


Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 


 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – The content will be deleted within 24 hours.

Leave a comment